Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy - Wikidata - wikimedia - TriplyDB

Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy

Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy

http://www.wikidata.org/entity/Q36001219

about

In vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studies The molecular biology of WHO grade I astrocytomas Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma A Sequentially Priming Phosphorylation Cascade Activates the Gliomagenic Transcription Factor Olig2.Pediatric high-grade glioma: biologically and clinically in need of new thinking CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers.TP53 Silencing Bypasses Growth Arrest of BRAFV600E-Induced Lung Tumor Cells in a Two-Switch Model of Lung Tumorigenesis.Detection of a Distinctive Genomic Signature in Rhabdoid Glioblastoma, A Rare Disease Entity Identified by Whole Exome Sequencing and Whole Transcriptome Sequencing Molecular markers in pediatric neuro-oncology.Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma.Pediatric gliomas as neurodevelopmental disorders Targeting Wee1 for the treatment of pediatric high-grade gliomas.Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model Pediatric diffuse intrinsic pontine glioma: can optimism replace pessimism?The evolving molecular genetics of low-grade glioma.Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade Gliomas.Recent Advances on the Molecular Pathology of Glial Neoplasms in Children and Adults.Molecular pathology of paediatric central nervous system tumours.Gliomatosis cerebri type 1 with extensive involvement of the spinal cord and BRAF V600E mutation.New strategies in pediatric gliomas: molecular advances in pediatric low-grade gliomas as a model.BRAF Mutations Open Doors for N-Ethyl-N-Nitrosourea-Induced Gliomagenesis.Next generation sequencing as an aid to diagnosis and treatment of an unusual pediatric brain cancer.BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas.Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E.Glioma.Recent Advances of Cell-Cycle Inhibitor Therapies for Pediatric Cancer.Molecular Basis of Pediatric Brain Tumors.p53 loss does not permit escape from BrafV600E-induced senescence in a mouse model of lung cancer.Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation.Reconstructing the molecular life history of gliomas.The cyclin-like protein Spy1 regulates growth and division characteristics of the CD133+ population in human glioma.Lgl1 controls NG2 endocytic pathway to regulate oligodendrocyte differentiation and asymmetric cell division and gliomagenesis

P2860

Q26820289-3765FC16-FD1F-4A26-8C60-4B13FDCA1FAF Q27010414-5438B2A3-0B27-4CB0-AC1A-92D577211AF6 Q27026323-C7434B55-3567-41F0-8038-0EECF3385F05 Q28533981-DE1747DF-0B56-42E4-8E8A-7A0219F220BC Q33571714-017551B6-DEC4-4B96-8BE0-E18D94BD7A5C Q33777868-40559A76-8921-4C16-8621-30CE65BE447F Q34004428-D7FC2EB8-5040-4B4A-96E2-E5E4D9E899BD Q35920997-3B671BB6-D108-4C1E-868E-7FDDEBC079B4 Q36038003-83C06E7F-BAA4-4BFA-BF17-835FAE87DC2E Q36344704-A7145E4F-28FD-446A-80E4-DBA48B784D93 Q36421110-FCAAC2BB-FEC7-4E08-8D6B-B843A143CF66 Q36561184-C615A3ED-865B-447F-BF05-714F505537EF Q36803476-4446541A-AEEA-445F-BF63-A6506CF50B9C Q37580495-64C2EE2B-1945-4628-B8A5-BD724B716558 Q37689031-43B711A7-E1EC-4651-8A7C-DC788BE4ECC4 Q38233425-DC09C2D0-BC54-486C-BF21-6FD5D1DCFD8C Q38349169-E9F2E269-C642-4159-BA1D-F72A3DCD2F9D Q38382607-BD938EBF-248B-4622-AB80-562A718C9767 Q38905187-D32049E5-FAAF-4AFF-9217-479ACF4D129D Q38971961-77F69F9B-3B82-4446-AF03-B16F744BE052 Q39291616-9E6BBB1C-E327-4A98-B527-F04A0B0FA1F1 Q41493335-E1026DD3-8858-49F4-A654-A04B8B97CFB3 Q41630229-39DF349C-9424-4DB6-9BEC-3D6C417DE480 Q42242778-7BB0CF6A-C112-49A0-BCFC-A39F563DAD11 Q42731010-905E250D-3AE1-4E77-81C8-6194772F47A0 Q46122173-50ABE0AA-D55A-4EED-B75B-E2A569E39C60 Q46132721-286D98DC-357B-4902-A061-3629D045DDF6 Q46820292-CF2A9D85-038E-423D-BE0C-45F1D98D3460 Q47447546-18FB19D9-4AFB-4A04-A681-7E0B7E8451E1 Q48023007-6B332A86-046D-4DD2-B35B-9A6E018F2276 Q48026380-F8C92399-2D72-4C6D-B6C9-B773459859E2 Q48258617-9F2A03D5-25D7-4F39-9703-E1370CF1B173 Q52608306-B9587828-F4E8-4B21-B90B-08722B0CBCC6 Q53050275-580A2EC5-AEE6-4A17-BDFB-F3B8B13F0DF1 Q58730941-A44203D9-842C-4978-9419-341F97760537

P2860

Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy

http://www.wikidata.org/entity/Q36001219

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Cooperative interactions of BR ...... s a basis for rational therapy

@ast

Cooperative interactions of BR ...... s a basis for rational therapy

@en

type

label

Cooperative interactions of BR ...... s a basis for rational therapy

@ast

Cooperative interactions of BR ...... s a basis for rational therapy

@en

prefLabel

Cooperative interactions of BR ...... s a basis for rational therapy

@ast

Cooperative interactions of BR ...... s a basis for rational therapy

@en

P1433

Q36001219-621112DD-9B5F-49C0-9720-3170ED404C05

P1476

Q36001219-01C2377E-5B66-47E3-8EBD-62EC15B39FDB

P2093

Q36001219-2A3E4263-EF1F-467C-8C58-3BF328DB51D0

Q36001219-429409A1-1F09-4297-86C3-61D71E646B88

Q36001219-45CF0E00-CD68-4383-A35D-26FB48314F88

Q36001219-5F9CF0A6-60CC-48AA-A585-5B0A69F1EAD0

Q36001219-673A1984-7793-45E1-B901-A8D88E327DCB

Q36001219-67EED6AC-C25E-4E2D-919C-4902BF2BC499

Q36001219-72D2540E-D106-45CB-9A92-71CC7C88EAF7

Q36001219-7C5C5E75-82C5-42AC-8493-1DA3782DAE91

Q36001219-7F89B276-EC90-4AA2-AC1D-0B523F84AA9F

Q36001219-8495DB56-FA03-46D4-AB61-CEC84DA3308D

P2860

Q36001219-0108D207-01C8-41D8-BFDA-E6851912CD47

Q36001219-027C3FD8-AE10-4905-AA9A-9EBA67956A3F

Q36001219-0445F2E7-C2FE-40A3-81B5-FF6A9245119F

Q36001219-0505C0D8-6A5B-44C2-9E48-D3CEA6E0902F

Q36001219-08EB2DE8-DAA7-40AB-B3C3-3865F53D1E80

Q36001219-0F6E7619-E42C-46F9-8049-045C05AB34DF

Q36001219-11C2212F-CF2E-4648-82AA-626B75531CBE

Q36001219-15170A02-4D23-45B7-A84B-15F147021868

Q36001219-15D7BCF8-69D1-4A1B-BDA8-D674DDEF1CCD

Q36001219-1E3DBF1C-0326-4EDB-8702-933A71ECED71

P304

Q36001219-C763A86A-3F65-4955-9611-C659DD7D9C8C

P31

Q36001219-00B27FCA-BC08-4F45-B9D2-FF8AFE40FCDC

P356

Q36001219-AC4877E3-AD2D-49BA-8CA7-7F58AD8160F2

P407

Q36001219-100048B4-E0D6-4956-A83C-863E5C8A8465

P433

Q36001219-A0671290-771D-4E33-8A90-3A21EF80FED4

P478

Q36001219-6ABDED31-6E9F-4994-ACB5-9B112F835DE1

P577

Q36001219-82B2A589-88CF-4A13-AD7D-289F39BDB223

P5875

Q36001219-C7E63C85-384F-4E9D-8BEA-EF8D67561C67

P698

Q36001219-2EAE2C0B-291C-4444-AECF-2014670BB778

P932

Q36001219-4228C254-6614-49C1-BD8E-9546515C0F98

P356

PNAS.1117255109

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Cooperative interactions of BR ...... s a basis for rational therapy

@en

P2093

Amélie Griveau

http://www.w3.org/2001/XMLSchema#string

Arie Perry

http://www.w3.org/2001/XMLSchema#string

C David James

http://www.w3.org/2001/XMLSchema#string

Claudia Petritsch

http://www.w3.org/2001/XMLSchema#string

David H Rowitch

http://www.w3.org/2001/XMLSchema#string

Emmanuelle Huillard

http://www.w3.org/2001/XMLSchema#string

Joanna J Phillips

http://www.w3.org/2001/XMLSchema#string

Martin McMahon

http://www.w3.org/2001/XMLSchema#string

Rebecca A Ihrie

http://www.w3.org/2001/XMLSchema#string

Rintaro Hashizume

http://www.w3.org/2001/XMLSchema#string

P2860

Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation.

Mutations of the BRAF gene in human cancer

Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma

Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

BRAFE600-associated senescence-like cell cycle arrest of human naevi

P304

8710-8715

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1117255109

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224958769

http://www.w3.org/2001/XMLSchema#string

P698

22586120

http://www.w3.org/2001/XMLSchema#string

P932

3365162

http://www.w3.org/2001/XMLSchema#string